Form 4: Axogen Director Joseph Tyndall Sells Over 26,000 Shares After Exercising Options

Axogen, Inc. Director Joseph A. Tyndall sold 26,931 shares of common stock at a weighted average price of $10.72 per share on June 10, 2025, following the exercise of stock options.

Summary

• Joseph A. Tyndall, a Director of Axogen, Inc. (AXGN), engaged in multiple transactions on June 10, 2025.
• He exercised stock options to acquire 7,586 shares of common stock at an exercise price of $6.30 per share. These options vested on September 1, 2023.
• Additionally, he exercised stock options to acquire 4,000 shares of common stock at an exercise price of $7.04 per share. These options vested on June 6, 2024.
• Following these acquisitions, Mr. Tyndall sold a total of 26,931 shares of common stock at a weighted average sale price of $10.72 per share. The sales occurred in multiple transactions with prices ranging from $10.69 to $10.83 per share.
• After these reported transactions, Mr. Tyndall's direct beneficial ownership of Axogen common stock is 0 shares.
• He still holds 14,248 unexercised employee stock options with an exercise price of $7.04, which vested on June 6, 2024, and expire on June 6, 2034.

Sentiment

Score: 4

Explanation: The director exercised options and sold all directly held common stock, which is a profitable transaction for the individual but could be interpreted by the market as a lack of strong conviction in the company's immediate future, or simply a personal liquidity event.

Positives

• The exercise of stock options indicates that the options were in-the-money, allowing the director to realize a profit.
• The sale price of $10.72 per share is significantly higher than the exercise prices of $6.30 and $7.04, indicating a profitable transaction for the director.

Negatives

• The sale of all directly held common stock by a director, including shares acquired through recent option exercises and previously held shares, could be interpreted as a lack of confidence in the company's near-term prospects or a move for personal liquidity.
• The complete divestment of direct common stock ownership by a director might raise questions among investors regarding future commitment.

Future Outlook

NA

Industry Context

This transaction is an individual insider trading activity and does not directly reflect broader industry trends. However, insider sales are often scrutinized by investors for signals about management's perception of the company's valuation or future prospects within its industry.

Related Party Transactions

• Joseph A. Tyndall, a Director of Axogen, Inc., exercised stock options to acquire 11,586 shares and subsequently sold 26,931 shares of Axogen common stock.

Stakeholder Impact

• Shareholders: May interpret the director's sale as a signal regarding the company's valuation or future prospects, potentially influencing their investment decisions.
• Employees: No direct impact mentioned, but general market sentiment can affect employee morale and stock-based compensation value.

Next Steps

• Investors may monitor future insider filings for Axogen, Inc. to observe any further changes in insider holdings or new director appointments.

Key Dates

Recommendation

Keywords

Axogen Inc., AXGN, SEC Form 4, Insider Trading, Stock Options, Director Stock Sale, Beneficial Ownership, Equity Transaction, Corporate Governance, Medical Devices